Blog
About

2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Modification to improve efficiency of sampling schedules for BA/BE testing of FDC anti-tuberculosis drugs.

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The assessment of rifampicin (RMP) containing fixed-dose combination (FDC) formulations using in vivo bioequivalence testing is widely accepted. It would be advantageous for both the drug regulatory authorities and drug manufacturers, for optimum minimum blood testing time intervals that encompass all anti-tuberculosis active constituents in the FDC to be established.

          Related collections

          Author and article information

          Affiliations
          [1 ] Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Rondebosch, South Africa. ggabriel@uctgsh1.uct.ac.za
          Journal
          Int. J. Tuberc. Lung Dis.
          The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
          1027-3719
          1027-3719
          Feb 2007
          : 11
          : 2
          17263289

          Comments

          Comment on this article